IMPLANON Implant / Subdermal
Etonogestrel
68mg/Implant
N.V. ORGANON
| Pack size | 1 Implant in Applicator |
|---|---|
| Dispensing mode | POM |
| Source | NETHERLANDS |
| Agent | CITY MEDICAL STORE |
| Retail Price | 663.50 AED |
Indications
IMPLANON Implant / Subdermal is used for:
Contraception
Adult Dose
Subdermal
Contraception
Adult: Each implant contains 68 mg of etonogestrel: 1 implant is inserted during the 1st 5 days of the menstrual cycle; remove within 3 yr of insertion.
Vaginal
Contraception
Adult: Each vaginal ring delivers 120 mcg of etonorgestrel and 15 mcg of ethinylestradiol daily. Insert one ring into the vagina on the 1st day of menstruation. Leave the ring in place continuously for 3 wk. Remove it after 3 wk for the 1 wk break during which breakthrough bleeding will occur. Insert a new ring 1 wk after removal of the previous ring.
Child Dose
Renal Dose
Administration
Contra Indications
Pregnancy, undiagnosed vag bleeding, severe arterial disease; liver adenoma; active liver disease; current or history of thromboembolic disorders; porphyria; after evacuation of hydatidiform mole; history of breast cancer.
Precautions
Heart disease, sex-steroid dependent cancer, history of ectopic pregnancy, malabsorption syndromes, functional ovarian cysts, recurrent cholestatic jaundice, history of jaundice in pregnancy; history of pruritus during pregnancy or of deterioration of otosclerosis; disturbances of lipid metabolism; history of CV or renal impairment, DM, asthma, epilepsy, migraine, depression; lactation. May develop bleeding irregularities.
Lactation: Small amounts excreted in breast milk; may nurse after the 4th postpartum week
Pregnancy-Lactation
Pregnancy
Contraindicated during pregnancy because there is no need for pregnancy prevention in woman who is already pregnant; epidemiologic studies and meta-analyses have not shown an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following maternal exposure to low dose CHCs prior to conception or during early pregnancy
Lactation
Small amounts of contraceptive steroids and/or metabolites, including etonogestrel are present in human milk; no significant adverse effects observed in production or quality of breast milk, or on physical and psychomotor development of breastfed infants
Hormonal contraceptives, including etonogestrel, can reduce milk production in breastfeeding mothers; this is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women; when possible, advise nursing mother about both hormonal and non-hormonal contraceptive options, as steroids may not be initial choice for these patients; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for hormonal contraceptive and any potential adverse effects on breastfed child from hormonal contraceptive or from underlying maternal condition
Interactions
Reduced efficacy with hepatic enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism. Changes in efficacy and safety of treatment when used in combination with protease inhibitors.
Adverse Effects
Side effects of Etonogestrel :
>10%
Oligomenorrhea (34%), Headache (25%), Vaginitis (24.5%), Amenorrhea (22%), Menorrhagia (18%), Weight gain (14%), Acne (13.5%), Breast pain (13%), Upper resp tract infection (13%), Pharyngitis (11%), Leucorrhea (10.5%)
1-10%
Back pain (7%), Depression (6%), Dizziness (7%), Dysmenorrhea (7%), Emotional lability (7%), Flu-like symptoms (8%), Insertion-site pain (9%), Nausea (6%), Nervousness (6%), Pain (6%)
Mechanism of Action
Etonogestrel is the active metabolite of desogestrel. It prevents pregnancy by suppressing ovulation, increasing viscosity of cervical mucous and inhibiting endometrial proliferation.
Note
IMPLANON 68mg/Implant Implant / Subdermal manufactured by N.V. ORGANON. Its generic name is Etonogestrel. IMPLANON is availble in United Arab Emirates.
Farmaco UAE drug index information on IMPLANON Implant / Subdermal is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.